MAPT and Alzheimer disease: All previous studies obtained comparable results using different tau tracers, such as 18F-PI-2620 and 18F-THK5351, but none of them used 18F-Flortaucipir which is the most widely applied and the only FDA-approved tracer establishing biomarker evidence of AD tau pathology in living people.